Author

Veronica M. Wessells

University of Colorado AnschutzORCID 0000-0001-9678-8848Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Developmental Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:scRNA-seq· 1 Approach:statistical model· 1

Frequent Co-Authors

Traci Renae LyonsiD· 2 shared Alan M. ElderiD· 1 shared Brendan Hinckley· 1 shared Heather Fairchild· 1 shared Lauren M. CozzensiD· 1 shared Pepper S. SchediniD· 1 shared Rachel N. SteinmetziD· 1 shared Sonali JindaliD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

9 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersDevelopmental Biology

Traci Renae LyonsORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Developmental BiologybioRxivPreprintMay 18, 2026

SOX9 and SEMA7A regulate cell plasticity in the postpartum mammary gland with implications for breast cancer

Lauren M. Cozzens, Brendan Hinckley, Alan M. Elder…·Traci Lyons

This study identifies SOX9 and SEMA7A as regulators of cell plasticity in postpartum mammary glands and links their dysregulation to breast cancer progression and metastasis.

DOI 10.64898/2026.05.14.725155

mousehuman

𝕏 PostBluesky

Cancer BiologybioRxivPreprintMay 21, 2025

Targeting Semaphorin 7a signaling in preclinical models of estrogen receptor-positive breast cancer

Rachel N. Steinmetz, Veronica M. Wessells, Heather Fairchild, Traci Renae Lyons

This study investigates SEMA7A's role in ER+ breast cancer resistance to endocrine therapy and shows that targeting SEMA7A with antibodies or PI3K inhibitors reduces tumor growth in preclinical models.

3 citations

mouseexperimental assay

𝕏 PostBluesky